Recently adopted names for antitumoral compounds (May 2012) - Noms d’antitumoraux adoptés récemment (mai 2012)

Name (nom)	Code name	Type	Target(s)
asparaginase Erwinia chrysanthemi (Erwinaze, Erwinase)	Crisantaspase	Enzyme	Breaks down the aminoacid asparagine
enzalutamide	MDV3100, MDV-3100	synthetic small molecule (signalling inhibitor)	Androgen receptor
nintedanib	BIBF1120, BIBF-1120, Vargatef	synthetic small molecule (antivascular agent	vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet derived growth factor receptor (PDGFR)

More on asparaginase Erwinia chrysanthemi

L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.

Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M, Pui CH. Cancer. 2011 Jan 15;117(2):238-49.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000881/pdf/nihms213986.pdf

More on enzalutamide

The evolution of antiandrogens: MDV3100 comes of age. Dumas L, Payne H, Chowdhury S. Expert Rev Anticancer Ther. 2012 Feb;12(2):131-3.

http://www.expert-reviews.com/doi/pdf/10.1586/era.11.210

More on nintedanib

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Klüglich M, du Bois RM. N Engl J Med. 2011 Sep 22;365(12):1079-87.

http://www.nejm.org/doi/full/10.1056/NEJMoa1103690#t=articleTop

New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond.

Gori B, Ricciardi S, Fulvi A, Intagliata S, Signore ED, de Marinis F.

Ther Clin Risk Manag. 2011;7:429-40.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253753/pdf/tcrm-7-429.pdf